Painchek (ASX:PCK) Stock Based Compensation: A$0.00 Mil (TTM As of Dec. 2025)


ASX:PCK Painchek Ltd ASX:PCK
50 GF Score
Price A$0.12
GF Value A$0.40
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Painchek Stock Based Compensation?

Painchek ASX:PCK +4.55% 50 Stock Based Compensation is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:PCK with a GF Score™ of 50/100 and a GF Value™ of A$0.40 (Possible Value Trap). The stock has 3 warning signs investors should review.

Painchek's Stock Based Compensation for the six months ended in Dec. 2025 was A$0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.00 Mil.

Painchek Stock Based Compensation Related Terms

Painchek Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Painchek's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Painchek Stock Based Compensation Chart

Painchek Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Painchek Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:PCK
50GF Score
Painchek Ltd ASX:PCK
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Painchek Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

What does a Stock Based Compensation of A$0.00 Mil mean?
Painchek (ASX:PCK) has a Stock Based Compensation of A$0.00 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Painchek and its competitors.
Is Painchek's Stock Based Compensation too high?
Painchek's current Stock Based Compensation is A$0.00 Mil. Overall, Painchek has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Painchek's Stock Based Compensation compare to VEEV and BTSG?
Painchek's Stock Based Compensation of A$0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Healthcare Providers & Services company?
A good Stock Based Compensation depends on the Healthcare Providers & Services industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Painchek and its competitors. Painchek's current Stock Based Compensation is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Painchek stock overvalued right now?
Based on GuruFocus' analysis, Painchek (ASX:PCK) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.40, compared to a current price of A$0.12 — trading 71.3% below its estimated fair value. The current Stock Based Compensation is A$0.00 Mil. Painchek's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Painchek (ASX:PCK), the current Stock Based Compensation is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Painchek (ASX:PCK) Overvalued in 2026?

Based on GuruFocus' analysis, Painchek stock appears to be undervalued. The current stock price of A$0.12 is trading 71.3% below its estimated GF Value™ of A$0.40. GuruFocus considers Painchek to be Possible Value Trap.

Key valuation signals for ASX:PCK:

  • Stock Based Compensation: A$0.00 Mil
  • GF Value™: A$0.40 vs. price of A$0.12 (71.3% below fair value)
  • GF Score™: 50/100 with 3 warning signs

No single metric tells the full story. See the ASX:PCK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Painchek Business Description

Address 35 Lime Street, Suite 401, Sydney, NSW, AUS, 2000
Painchek Ltd is engaged in the development and commercialization of mobile medical device applications that provide pain assessment for individuals who are unable to communicate pain with carers. It operates in one segment, namely the sale of its pain assessment solutions. Its geographic segments include Australia, the United Kingdom, and Other countries, of which it generates the majority of its revenue from Australia.
50GF Score

Get the complete analysis for ASX:PCK

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.12
Price
A$0.40
GF Value